Cargando…

Termination of Vernakalant-Resistant Atrial Fibrillation by Inhibition of Small-Conductance Ca(2+)-Activated K(+) Channels in Pigs

BACKGROUND: Evidence has emerged that small-conductance Ca(2+)-activated K(+) (SK) channels constitute a new target for treatment of atrial fibrillation (AF). SK channels are predominantly expressed in the atria as compared with the ventricles. Various marketed antiarrhythmic drugs are limited by ve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diness, Jonas Goldin, Skibsbye, Lasse, Simó-Vicens, Rafel, Santos, Joana Larupa, Lundegaard, Pia, Citerni, Carlotta, Sauter, Daniel Rafael Peter, Bomholtz, Sofia Hammami, Svendsen, Jesper Hastrup, Olesen, Søren-Peter, Sørensen, Ulrik S., Jespersen, Thomas, Grunnet, Morten, Bentzen, Bo Hjorth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647113/ https://www.ncbi.nlm.nih.gov/pubmed/29018164 http://dx.doi.org/10.1161/CIRCEP.117.005125

Ejemplares similares

Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man
por: Bentzen, Bo Hjorth, et al.
Publicado: (2020)

The K(Ca)2 Channel Inhibitor AP14145, But Not Dofetilide or Ondansetron, Provides Functional Atrial Selectivity in Guinea Pig Hearts
por: Kirchhoff, Jeppe Egedal, et al.
Publicado: (2019)

The K(Ca)2 Channel Inhibitor AP30663 Selectively Increases Atrial Refractoriness, Converts Vernakalant-Resistant Atrial Fibrillation and Prevents Its Reinduction in Conscious Pigs
por: Diness, Jonas Goldin, et al.
Publicado: (2020)

Inhibition of K(Ca)2 Channels Decreased the Risk of Ventricular Arrhythmia in the Guinea Pig Heart During Induced Hypokalemia
por: Diness, Jonas Goldin, et al.
Publicado: (2020)

Inhibition of K(Ca)2 and K(v)11.1 Channels in Pigs With Left Ventricular Dysfunction
por: Citerni, Carlotta, et al.
Publicado: (2020)

2,6-Bis(2-Benzimidazolyl)Pyridine (BBP) Is a Potent and Selective Inhibitor of Small Conductance Calcium-Activated Potassium (SK) Channels
por: Simó-Vicens, Rafel, et al.
Publicado: (2018)

Effective termination of atrial fibrillation by SK channel inhibition is associated with a sudden organization of fibrillatory conduction
por: Gatta, Giulia, et al.
Publicado: (2021)

Characterization of Atrial and Ventricular Structural Remodeling in a Porcine Model of Atrial Fibrillation Induced by Atrial Tachypacing
por: Citerni, Carlotta, et al.
Publicado: (2020)

Whole-Exome Sequencing Implicates Neuronal Calcium Channel with Familial Atrial Fibrillation
por: Vad, Oliver Bundgaard, et al.
Publicado: (2022)

Role of Calcium-activated Potassium Channels in Atrial Fibrillation Pathophysiology and Therapy
por: Diness, Jonas G., et al.
Publicado: (2015)

Investigating gene-microRNA networks in atrial fibrillation patients with mitral valve regurgitation
por: Larupa Santos, Joana, et al.
Publicado: (2020)

A Novel Loss-of-Function Variant in the Chloride Ion Channel Gene Clcn2 Associates with Atrial Fibrillation
por: Hansen, Thea Hyttel, et al.
Publicado: (2020)

Small conductance calcium activated K(+) channel inhibitor decreases stretch induced vulnerability to atrial fibrillation
por: Yan, Yannan, et al.
Publicado: (2021)

Introducing Vernakalant into Clinical Practice
por: Hall, Angela JM, et al.
Publicado: (2019)

Antiarrhythmic effect of the Ca(2+)-activated K(+) (SK) channel inhibitor ICA combined with either amiodarone or dofetilide in an isolated heart model of atrial fibrillation
por: Kirchhoff, Jeppe Egedal, et al.
Publicado: (2016)

Central and Peripheral GABA(A) Receptor Regulation of the Heart Rate Depends on the Conscious State of the Animal
por: Bentzen, Bo Hjorth, et al.
Publicado: (2011)

Pharmacological inhibition of I(K) (1) by PA‐6 in isolated rat hearts affects ventricular repolarization and refractoriness
por: Skarsfeldt, Mark A., et al.
Publicado: (2016)

Vernakalant and electrical cardioversion for AF – Safe and effective
por: Simon, Alexander, et al.
Publicado: (2019)

Meta-analysis of effect of vernakalant on conversion of atrial fibrillation
por: Yan, He, et al.
Publicado: (2013)

Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update
por: Tsuji, Yukiomi, et al.
Publicado: (2013)

Body Weight Counts—Cardioversion with Vernakalant or Ibutilide at the Emergency Department
por: Lindmayr, Teresa, et al.
Publicado: (2022)

BK channel activators and their therapeutic perspectives
por: Bentzen, Bo H., et al.
Publicado: (2014)

Vernakalant for Cardioversion of Recent-Onset Atrial Fibrillation in the Emergency Department: The SPECTRUM Study
por: Bager, Johan-Emil, et al.
Publicado: (2022)

Suitability, Efficacy, and Safety of Vernakalant for New Onset Atrial Fibrillation in Critically Ill Patients
por: Rudiger, Alain, et al.
Publicado: (2014)

The Vernakalant Story: How Did It Come to Approval in Europe and What is the Delay in the U.S.A?
por: A, John Camm MD
Publicado: (2014)

Vernakalant in Atrial Fibrillation: A Relatively New Weapon in the Armamentarium Against an Old Enemy
por: Kossaify, Antoine
Publicado: (2019)

Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study
por: Lévy, Samuel, et al.
Publicado: (2020)

Inhibition of Small Conductance Calcium-Activated Potassium (SK) Channels Prevents Arrhythmias in Rat Atria During β-Adrenergic and Muscarinic Receptor Activation
por: Skibsbye, Lasse, et al.
Publicado: (2018)

Regulation of Kv1.4 potassium channels by PKC and AMPK kinases
por: Andersen, Martin Nybo, et al.
Publicado: (2017)

Ventricular Arrhythmias in First Acute Myocardial Infarction: Epidemiology, Mechanisms, and Interventions in Large Animal Models
por: Sattler, Stefan Michael, et al.
Publicado: (2019)

First Clinical Study with AP30663 ‐ a K(Ca)2 Channel Inhibitor in Development for Conversion of Atrial Fibrillation
por: Gal, Pim, et al.
Publicado: (2020)

Amiodarone Treatment in the Early Phase of Acute Myocardial Infarction Protects Against Ventricular Fibrillation in a Porcine Model
por: Sattler, Stefan M., et al.
Publicado: (2019)

Increased Density of Endogenous Adenosine A(2A) Receptors in Atrial Fibrillation: From Cellular and Porcine Models to Human Patients
por: Godoy-Marín, Héctor, et al.
Publicado: (2023)

Hemodynamic effects of Vernakalant in cardio-surgical ICU-patients treated for recent-onset postoperative atrial fibrillation
por: Schnaubelt, S., et al.
Publicado: (2020)

Inhibition of Adenosine Pathway Alters Atrial Electrophysiology and Prevents Atrial Fibrillation
por: Soattin, Luca, et al.
Publicado: (2020)

Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation: A protocol for systematic review and meta-analysis
por: Li, Hong, et al.
Publicado: (2022)

Antiarrhythmic and Electrophysiologic Effects of Flecainide on Acutely Induced Atrial Fibrillation in Healthy Horses
por: Haugaard, M.M., et al.
Publicado: (2014)

Cardiac magnetic resonance systematically overestimates mitral regurgitations by the indirect method
por: Bertelsen, Litten, et al.
Publicado: (2020)

Are we at the Goal Line with the Novel Oral Anticoagulants and Have We Reached the End of the Line for Dronedarone and Vernakalant – or is There More to Come?
por: Reiffel, James A
Publicado: (2014)

Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial
por: Beatch, Gregory N., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nke997bernut58gp967aj8ma8j